BenevolentAI's core product is an "AI brain" built by a team of scientists to ingest and compute billions of data points across domains such as health and material science. That platform is used by its Benevolent Bio division to accelerate drug discovery and by other teams to explore materials and energy applications. Benevolent Bio currently has two drugs in more advanced stages, including a Parkinson's drug in Phase 2B and an ALS program projected to be about five years from trials. The company is expanding into adjacent areas like material science, agriculture, and veterinary science to pursue high‑heat materials and next‑generation battery chemistries. Founded in 2013 and based in London, BenevolentAI has 155 employees and projects headcount of about 300 by year‑end. Financially, it raised $115M in the latest venture round at a $2.1B post‑money valuation and has raised more than $200M to date.

Total raised

$115M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2018